7498 Results (Page 204 of 300)
Pharmaceuticals Markets Research Reports
France Acute Lymphocytic Leukemia (ALL) Therapeutics Market Analysis
The France Acute Lymphocytic Leukemia (ALL) Therapeutics Market was valued at US $91 Mn in 2022, and is predicted to grow at (CAGR) of 6.8% from 2023 to 2030, to US $154 Mn by 2030. The key drivers of this industry include a surge in the incidence of acute lymphocytic Leukemia cases, rising awareness and diagnosis, increased government funding initiatives and other factors. The industry is primarily dominated by players such as Bristol Myers Squibb, Novartis, Sanofi, Pfizer Inc, among other players
US Addiction Therapeutics Market Analysis
US addiction therapeutics market was valued at $4242 Mn in 2022 and is estimated to reach $6220 Mn in 2030, exhibiting a CAGR of 4.9% during the forecast period. The market's growth is attributed to government initiatives to combat chronic drug use and advance prescription, as well as growing support for new drugs and the launch of cutting-edge therapies to treat addiction. Driving vital players working in the market include Pfizer, Sun Pharmaceutical Industries, Teva Pharmaceutical Industries, Titan Pharmaceutical, Indivior, Novartis, Cipla, Mylan, Glenmark and Alkermes
Vietnam Autosomal Dominant Polycystic Kidney Disease Therapeutics Market Analysis
The Vietnam Autosomal Dominant Polycystic Kidney Disease Therapeutics Market was valued at US $6 Mn in 2022 and is predicted to grow at a CAGR of 6.03% from 2023 to 2030, to US $9 Mn by 2030. The key drivers of this industry include the upward trend in the prevalence of autosomal dominant polycystic kidney disease, government initiatives, increased awareness, and other factors. The industry is primarily dominated by players such as Otsuka, AceLink, Palladio, Reata, Xortx, Regulus, Exelixis, Sanofi and other players
US Autosomal Dominant Polycystic Kidney Disease Therapeutics Market Analysis
The US Autosomal Dominant Polycystic Kidney Disease Therapeutics Market was valued at US $462 Mn in 2022 and is predicted to grow at a CAGR of 3.8% from 2023 to 2030, to US $623 Mn by 2030. The key drivers of this industry include the upward trend in the incidence of autosomal dominant polycystic kidney disease, the aging population, increased awareness, and other factors. The industry is primarily dominated by players such as Otsuka, Sanofi, Reata, and Janssen Pharmaceutical, among others
UK Autosomal Dominant Polycystic Kidney Disease Therapeutics Market Analysis
The UK Autosomal Dominant Polycystic Kidney Disease Therapeutics Market was valued at US $29 Mn in 2022 and is predicted to grow at (CAGR) of 3.8% from 2023 to 2030, to US $39 Mn by 2030. The key drivers of this industry include the upward trend in the prevalence of autosomal dominant polycystic kidney disease, unmet needs, government initiatives, and other factors. The industry is primarily dominated by players such as Otsuka, AceLink, Palladio, Reata, Xortx, Regulus, among others
UAE Autosomal Dominant Polycystic Kidney Disease Therapeutics Market Analysis
The UAE Autosomal Dominant Polycystic Kidney Disease Therapeutics Market was valued at US $6 Mn in 2022, and is predicted to grow at (CAGR) of 6.8% from 2023 to 2030, to US $9 Mn by 2030. The key drivers of this industry include the upward trend in the incidence of autosomal dominant polycystic kidney disease, increased awareness, and other factors. The industry is primarily dominated by players such as Otsuka, Sanofi, Reta, Regulus, and AceLink Therapeutics, among others
Spain Autosomal Dominant Polycystic Kidney Disease Therapeutics Market Analysis
The Spain Autosomal Dominant Polycystic Kidney Disease Therapeutics Market was valued at US $21 Mn in 2022, and is predicted to grow at (CAGR) of 4.8% from 2023 to 2030, to US $31 Mn by 2030. The key drivers of this industry include the upward trend in the incidence of autosomal dominant polycystic kidney disease, strong healthcare infrastructure, and other factors. The industry is primarily dominated by players such as Otsuka, Sanofi, Pfizer, Palladio, Reata, Xortx, Janssen among others
South Africa Autosomal Dominant Polycystic Kidney Disease Therapeutics Market Analysis
The South Africa Autosomal Dominant Polycystic Kidney Disease Therapeutics Market was valued at US $7 Mn in 2022, and is predicted to grow at (CAGR) of 7.03% from 2023 to 2030, to US $12 Mn by 2030. The key drivers of this industry include the several government initiatives and policies to support rare diseases and increased awareness among the population regarding the condition. The industry is primarily dominated by players such as Otsuka Pharmaceutical, AceLink Therapeutics, Palladio Biosciences, Reata Pharmaceutica, Xortx, Regulus Therapeutics, and Galapagos NV among others
Singapore Autosomal Dominant Polycystic Kidney Disease Therapeutics Market Analysis
The Singapore Autosomal Dominant Polycystic Kidney Disease Therapeutics Market was valued at US $1 Mn in 2022 and is predicted to grow at a CAGR of 6.4% from 2023 to 2030, to US $2 Mn by 2030. The key drivers of this industry include the upward trend in the prevalence of autosomal dominant polycystic kidney disease, government initiatives, increased awareness and other factors. The industry is primarily dominated by players such as Alebund, AceLink, Galapagos NV, Reata, Xortx, Regulus among others
Saudi Arabia Autosomal Dominant Polycystic Kidney Disease Therapeutics Market Analysis
The Saudi Arabia Autosomal Dominant Polycystic Kidney Disease Therapeutics Market was valued at US $19 Mn in 2022, and is predicted to grow at a CAGR of 7.3% from 2023 to 2030, to US $33 Mn by 2030. The key drivers of this industry include the upward trend in the incidence of autosomal dominant polycystic kidney disease, increased awareness, and other factors. The industry is primarily dominated by players such as Otsuka, Sanofi, Pfizer, and Janssen Pharmaceutical, among others
Philippines Autosomal Dominant Polycystic Kidney Disease Therapeutics Market Analysis
The Philippines Autosomal Dominant Polycystic Kidney Disease Therapeutics Market was valued at US $2 Mn in 2022 and is predicted to grow at a CAGR of 6.3% from 2023 to 2030, to US $4 Mn by 2030. The key drivers of this industry include the upward trend in the prevalence of autosomal dominant polycystic kidney disease, government initiatives, increased awareness, and other factors. The industry is primarily dominated by players such as Otsuka, AceLink, Palladio, Reata, Xortx, Regulus, among others
Mexico Autosomal Dominant Polycystic Kidney Disease Therapeutics Market Analysis
The Mexico Autosomal Dominant Polycystic Kidney Disease Therapeutics Market was valued at US $17 Mn in 2022, and is predicted to grow at a CAGR of 6.05% from 2023 to 2030, to US $26 Mn by 2030. The key drivers of this industry include the upward trend in the incidence of autosomal dominant polycystic kidney disease, government initiatives, and other factors. The industry is primarily dominated by players such as Otsuka, Sanofi, Roche, Biogen, AstraZeneca, Janssen among others
Malaysia Autosomal Dominant Polycystic Kidney Disease Therapeutics Market Analysis
The Malaysia Autosomal Dominant Polycystic Kidney Disease Therapeutics Market was valued at US $ 1.8 Mn in 2022, and is predicted to grow at (CAGR) of 6% from 2023 to 2030, to US $ 2.9 Mn by 2030. The key drivers of this industry include the upward trend in the prevalence of autosomal dominant polycystic kidney disease, government initiatives, advanced treatment options and other factors. The industry is primarily dominated by players such as Otsuka, AceLink, Palladio, Reata, Xortx, Regulus among others
Kenya Autosomal Dominant Polycystic Kidney Disease Therapeutics Market Analysis
The Kenya Autosomal Dominant Polycystic Kidney Disease Therapeutics Market was valued at US $0.8 Mn in 2022, and is predicted to grow at (CAGR) of 6.9% from 2023 to 2030, to US $1.4 Mn by 2030. The key drivers of this industry include the several government initiatives and policies to support rare diseases and increased awareness among the population regarding the condition. The industry is primarily dominated by players such as Otsuka Pharmaceutical, AceLink Therapeutics, Palladio Biosciences, Reata Pharmaceutica, Xortx, Regulus Therapeutics, Galapagos NV among others
Japan Autosomal Dominant Polycystic Kidney Disease Therapeutics Market Analysis
The Japan Autosomal Dominant Polycystic Kidney Disease Therapeutics Market was valued at US $68 Mn in 2022 and is predicted to grow at a CAGR of 6.3% from 2023 to 2030, to US $111 Mn by 2030. The key drivers of this industry include the upward trend in the prevalence of autosomal dominant polycystic kidney disease, government initiatives, collaborations, and other factors. The industry is primarily dominated by players such as Otsuka, AceLink, Palladio, Reata, Xortx, Regulus, among others
Indonesia Autosomal Dominant Polycystic Kidney Disease Therapeutics Market Analysis
The Indonesia Autosomal Dominant Polycystic Kidney Disease Therapeutics Market was valued at US $6.6 Mn in 2022, and is predicted to grow at (CAGR) of 5.8% from 2023 to 2030, to US $10.4 Mn by 2030. The key drivers of this industry include the upward trend in the prevalence of autosomal dominant polycystic kidney disease, healthcare infrastructure, economic growth, and other factors. The industry is primarily dominated by players such as Otsuka, AceLink, Palladio, Reata, Xortx, Regulus, among others
Germany Autosomal Dominant Polycystic Kidney Disease Therapeutics Market Analysis
The Germany Autosomal Dominant Polycystic Kidney Disease Therapeutics Market was valued at US $ 40 Mn in 2022, and is predicted to grow at (CAGR) of 4% from 2023 to 2030, to US $55 Mn by 2030. The key drivers of this industry include the upward trend in the incidence of autosomal dominant polycystic kidney disease, strong healthcare infrastructure, and other factors. The industry is primarily dominated by players such as Otsuka, Sanofi, Roche, Biogen, Reata, Xortx, Janssen among others
France Autosomal Dominant Polycystic Kidney Disease Therapeutics Market Analysis
The France Autosomal Dominant Polycystic Kidney Disease Therapeutics Market was valued at US$30 Mn in 2022 and is predicted to grow at a CAGR of 4.80% from 2023 to 2030, reaching US million by 2030. The key drivers of this industry include the upward trend in the incidence of autosomal dominant polycystic kidney disease, strong healthcare infrastructure and other factors. The industry is primarily dominated by players such as Otsuka, Sanofi, Roche, Biogen, AstraZeneca, Janssen among others
Egypt Autosomal Dominant Polycystic Kidney Disease Therapeutics Market Analysis
The Egypt Autosomal Dominant Polycystic Kidney Disease Therapeutics Market was valued at US$3 Mn in 2022, and is predicted to grow at a CAGR of 7.3% from 2023 to 2030, to US$5 Mn by 2030. The key drivers of this industry include the upward trend in the prevalence of autosomal dominant polycystic kidney disease, healthcare infrastructure growth, and other factors. The industry is primarily dominated by players such as Otsuka Pharmaceuticals, AceLink, Palladio, Reata, Xortx, Regulus, Exelixis, Sanofi, and other players.
China Autosomal Dominant Polycystic Kidney Disease Therapeutics Market Analysis
The China Autosomal Dominant Polycystic Kidney Disease Therapeutics Market was valued at US$88 Mn in 2022 and is predicted to grow at a CAGR of 7.3% from 2023 to 2030, to US$155 Mn by 2030. The key drivers of this industry include the upward trend in the prevalence of autosomal dominant polycystic kidney disease, healthcare infrastructure, economic growth, and other factors. The industry is primarily dominated by players such as Otsuka, AceLink, Palladio, Reata, Xortx, and Regulus, among others
Canada Autosomal Dominant Polycystic Kidney Disease Therapeutics Market Analysis
The Canada Autosomal Dominant Polycystic Kidney Disease Therapeutics Market was valued at US $88 Mn in 2022, and is predicted to grow at (CAGR) of 5.8% from 2023 to 2030, to US $138 Mn by 2030. The key drivers of this industry include the upward trend in the incidence of autosomal dominant polycystic kidney disease, the aging population, novel therapeutics, and other factors. The industry is primarily dominated by players such as Pfizer, Sanofi, Novartis, and Teva Pharmaceutical, among others
Brazil Autosomal Dominant Polycystic Kidney Disease Therapeutics Market Analysis
The Brazil Autosomal Dominant Polycystic Kidney Disease Therapeutics Market was valued at US $ 28 Mn in 2022, and is predicted to grow at (CAGR) of 6.8% from 2023 to 2030, to US $47 Mn by 2030. The key drivers of this industry include the upward trend in the incidence of autosomal dominant polycystic kidney disease, government initiatives and other factors. The industry is primarily dominated by players such as Otsuka, Sanofi, Roche, Biogen, Vertex, Janssen among others
Germany Adult Malignant Glioma Therapeutics Market Analysis
The Germany Adult Glioma Therapeutics Market is valued at around $81 Mn in 2022 and is projected to reach $139 Mn by 2030, exhibiting a CAGR of 7.1% during the forecast period. The market is set for growth due to a supportive healthcare system, substantial funding for research and development and advancements such as precision medicines and telemedicine, all contributing to an expanding market driven by a rising incidence of glioma. Key players in the Germany Adult Malignant Glioma Therapeutics Market include companies like Roche, Merck & Co., Celyad, AbbVie, CureVac, Celyad, Vaxxilon, Oncolytics Biotech, Elekta, Varian Medical Systems etc
UAE Diabetes Therapeutics Market Analysis
UAE's diabetes therapeutics market is expected to grow from $719 Mn in 2022 to $1,622 Mn in 2030 with a CAGR of 10.7% for the forecasted year 2022-30. The development of novel and ground-breaking treatment options along with supportive government programs like Thiqa and Saada are driving the growth of the market. The UAE diabetes therapeutics market is segmented by type, application, drug, route of administration, and distribution channel. Rimo Pharmaceuticals, Medspero Pharma, and Boehringer Ingelheim are the major players in the UAE diabetes therapeutics market.
Vietnam Age-Related Macular Degeneration Therapeutics Market Analysis
The Vietnam Age-Related Macular Degeneration (AMD) Therapeutics Market was valued at US $54 Mn in 2022 and is predicted to grow at a CAGR of 9.13% from 2023 to 2030, to US $109 Mn by 2030. The key drivers of this industry include the upward trend in the prevalence of age-related macular degeneration, improved healthcare infrastructure, and other factors. The industry is primarily dominated by players such as Regeneron Pharmaceuticals, Novartis, Bayer, Roche, and Genetech, among others
